跳转至内容
Merck
CN
  • SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest.

SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest.

Die Pharmazie (2012-12-06)
J Y Li, J Y Huang, B Xing, K W Ren, M Li, D Wei, P Y Gu, G Chen, B Gu, G F Zhang, W X Hu
摘要

SP600125 is a well studied inhibitor of c-Jun N-terminal kinase (JNK). Its direct biochemical effects on JNK-inactive tumor cells are usually ignored. In this study, we investigated the effects of SP600125 on JNK-inactive U251 human glioblastoma cells. Our results demonstrate that, 20 microM or more SP600125 can induce significant cell growth inhibition and cell-cycle G2/M phase arrest in U251 cells. Interestingly, we also found that SP600125 can stop the duplicated chromosomes from separating into two cells and the karyokinesis progression. Our study opened up a new perspective for further studies involved in JNK inhibitors or anti-glioma therapy.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
双苯并咪唑 H 33342 三盐酸盐, ≥98% (HPLC)
Sigma-Aldrich
双苯并咪唑 H 33342 三盐酸盐, suitable for fluorescence, ≥97.0% (HPLC)